Preferreds convert into 1,000 shares at a price of $1.50 per share
By Rebecca Melvin
New York, Feb. 6 – Oncothyreon Inc. priced about $2 million of series B convertible preferred stock, or 1,333 shares at $1,500 per share, concurrently with about $20 million of common stock, or 13.5 million shares at $1.50 each, according to a news release.
Jefferies LLC was bookrunner of the separate offerings.
The preferreds convert into common stock at a ratio of 1,000 shares per preferred, for a conversion price of $1.50 per share, the same price that the common stock was sold at.
Conversion is prohibited if it would lead to the holder owning more than 4.99% of the company’s common stock.
Proceeds will be used to fund development of its therapeutic products, including ONT-380, ONT-10, its small molecule Chk1 program and its protocell technology as well as for general corporate purposes, including other discovery or preclinical research and product development.
A portion of the proceeds will be used to acquire or license new product candidates or technology that could result in other product candidates.
Oncothyreon priced $20 million of series A convertible preferred stock, or 10,000 shares at $2,000 each, in a private offering in September.
Oncothyreon is a Seattle-based biotechnology company.
Issuer: | Oncothyreon Inc.
|
Issue: | Series B convertible preferred shares
|
Amount: | $2 million, or 1,333 preferred shares
|
Concurrent offering: | $20 million of common stock
|
Bookrunner: | Jefferies LLC
|
Price: | Par, $1,500 per share
|
Conversion price: | $1.50
|
Conversion ratio: 1,000
|
Pricing date: | Feb. 5
|
Settlement date: | Feb. 11
|
Distribution: | Registered
|
Stock symbol: | Nasdaq: ONTY
|
Stock reference price: | $1.50
|
Stock price: | $1.57 as of close Feb. 5
|
Market capitalization: | $137.3 million
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.